Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Minerva Neurosciences stock

Learn how to easily invest in Minerva Neurosciences stock.

Minerva Neurosciences is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Minerva Neurosciences stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – NERV. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance



  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Minerva Neurosciences stock price (NASDAQ: NERV)

Use our graph to track the performance of NERV stocks over time.

Minerva Neurosciences shares at a glance

Information last updated 2023-01-26.
Latest market close$2.21
52-week range$1.26 - $15.27
50-day moving average $2.67
200-day moving average $4.50
Wall St. target price$6.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.19

Buy Minerva Neurosciences stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Minerva Neurosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Minerva Neurosciences price performance over time

Historical closes compared with the close of $2.21 from 2023-01-26

1 week (2023-01-20) 13.33%
1 month (2022-12-27) -5.96%
3 months (2022-10-27) -22.73%
6 months (2022-07-27) -12.65%
1 year (2022-01-26) 202.24%
2 years (2021-01-27) -31.37%
3 years (2020-01-27) 8.18
5 years (2018-01-26) 6.6

Minerva Neurosciences financials

Gross profit TTM $-16,838,947
Return on assets TTM -20.93%
Return on equity TTM -675.09%
Profit margin 0%
Book value $-2.67
Market capitalisation $11.7 million

TTM: trailing 12 months

Minerva Neurosciences share dividends

We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.

Have Minerva Neurosciences's shares ever split?

Minerva Neurosciences's shares were split on a 1:8 basis on 20 June 2022. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Minerva Neurosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Minerva Neurosciences shares which in turn could have impacted Minerva Neurosciences's share price.

Minerva Neurosciences share price volatility

Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $1.26 up to $15.27. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is -0.0687. This would suggest that Minerva Neurosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Minerva Neurosciences has bucked the trend.

Minerva Neurosciences overview

Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc.

Frequently asked questions

What percentage of Minerva Neurosciences is owned by insiders or institutions?
Currently 3.425% of Minerva Neurosciences shares are held by insiders and 38.557% by institutions.
How many people work for Minerva Neurosciences?
Latest data suggests 9 work at Minerva Neurosciences.
When does the fiscal year end for Minerva Neurosciences?
Minerva Neurosciences's fiscal year ends in December.
Where is Minerva Neurosciences based?
Minerva Neurosciences's address is: 1601 Trapelo Road, Waltham, MA, United States, 02451
What is Minerva Neurosciences's ISIN number?
Minerva Neurosciences's international securities identification number is: US6033802058
What is Minerva Neurosciences's CUSIP number?
Minerva Neurosciences's Committee on Uniform Securities Identification Procedures number is: 603380106

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site